United Therapeutics Corporation (UTHR)
After hours:
| Previous close | 235.31 |
| Open | 234.67 |
| Bid | 236.84 x 100 |
| Ask | 237.42 x 100 |
| Day's range | 234.31 - 240.74 |
| 52-week range | 204.44 - 261.54 |
| Volume | |
| Avg. volume | 448,291 |
| Market cap | 11.15B |
| Beta (5Y monthly) | 0.55 |
| PE ratio (TTM) | 11.96 |
| EPS (TTM) | 19.81 |
| Earnings date | 01 May 2024 - 06 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 292.25 |
- Business Wire
United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the American Thoracic Society 2024 International Conference
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., April 16, 2024--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that recent research across its commercial and development portfolio will be presented at the American Thoracic Society (ATS) International Conference in San Diego on May 17-22, 2024. At ATS, United Therapeutics will host an educational industry theater on implementing treprostinil induction strategies in pulmonary hypertension, and the
GuruFocus.comInsider Sell: Chairperson & CEO Martine Rothblatt Sells 30,000 Shares of United ...
Martine Rothblatt, Chairperson & Chief Executive Officer of United Therapeutics Corp (NASDAQ:UTHR), sold 30,000 shares of the company on April 4, 2024, according to a recent SEC filing.
GuruFocus.comInsider Sell: EVP & GENERAL COUNSEL Paul Mahon Sells 6,000 Shares of United Therapeutics ...
Paul Mahon, EVP & GENERAL COUNSEL of United Therapeutics Corp (NASDAQ:UTHR), sold 6,000 shares of the company on April 4, 2024, according to a recent SEC filing.
